Drug Ther Bull. 2011 Jul;49(7):81-4. doi: 10.1136/dtb.2011.02.0044.
Systemic lupus erythematosus (SLE) is a complex multisystem autoimmune disease with a relapsing and remitting course.1 In the UK, the prevalence has been estimated as 25 per 100,000, and the annual incidence as 5.3 for females and 0.7 for males per 100,000.2 Mortality rates for people with SLE have improved over the years. Here we update our 1996 review3 on the management of SLE and discuss recent developments, including the use of biological agents.
系统性红斑狼疮(SLE)是一种复杂的多系统自身免疫性疾病,病程呈复发缓解型。在英国,估计患病率为每10万人中有25例,年发病率为女性每10万人中有5.3例,男性每10万人中有0.7例。多年来,SLE患者的死亡率有所改善。在此,我们更新了1996年关于SLE管理的综述,并讨论了近期的进展,包括生物制剂的使用。